Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Licenses Osteoporosis Drug Targets From Galapagos

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth agrees to second milestone stemming from 2003 agreement, selecting three novel Galapagos targets for osteoporosis.

You may also be interested in...



Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal

Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.

Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal

Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.

Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis

Firm continues to plan an additional submission this year for an osteoporosis treatment claim.

Related Content

Topics

UsernamePublicRestriction

Register

PS066240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel